Adaptimmune stock plunges after announcing Nasdaq delisting plans
LAWRENCEVILLE, N.J. - IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company with a market capitalization of $12.56 million, presented new translational data from its Phase 2 OVATION 2 Study of IMNN-001, a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer, at the American Association for Cancer Research Special Conference in Denver. According to InvestingPro analysis, the stock is currently trading near its 52-week low, though appears undervalued based on Fair Value metrics.
The study evaluated 112 participants treated with IMNN-001 administered intraperitoneally in addition to standard-of-care neoadjuvant and adjuvant chemotherapy.
According to the company’s presentation, the data showed a positive shift in the tumor microenvironment to favorable immune stimulatory T cell ratios in most participants treated with IMNN-001. The treatment increased anti-tumor CD8+ and myeloid dendritic cells in 50-80% of paired samples while decreasing immunosuppressive markers in 65-80% of samples.
Douglas V. Faller, Chief Medical Officer of IMUNON, stated that these findings reinforce the overall survival results previously reported from the OVATION 2 Study, which showed a median 13-month increase in overall survival compared to standard care alone.
The company is currently conducting the pivotal Phase 3 OVATION 3 Study of IMNN-001, with four trial sites activated and enrolling patients. IMUNON reported that the Phase 3 trial is supported by data from the Phase 2 study that demonstrated improved survival outcomes, particularly in patients who received poly ADP-ribose polymerase inhibitors as part of maintenance therapy. InvestingPro data shows the company maintains a healthy balance sheet with more cash than debt, though it’s currently experiencing rapid cash burn, which could impact trial progression.
IMNN-001 uses the company’s TheraPlas® platform technology to deliver IL-12 DNA plasmid vector encased in nanoparticles, enabling persistent local secretion of the IL-12 protein, which can induce anticancer immunity.
Epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S., with approximately 20,000 new cases annually and 70% diagnosed at advanced stages.
This information is based on a press release statement from the company.
In other recent news, Imunon Inc. reported its second-quarter earnings for 2025, which showed a significant earnings per share (EPS) miss. The company posted an EPS of -$2.15, which was substantially lower than the expected -$0.32, resulting in a surprise of 571.88%. This larger-than-expected loss has raised investor concerns. Additionally, IMUNON, Inc. will present new translational data from its Phase 2 OVATION 2 Study of IMNN-001 at the American Association for Cancer Research Special Conference. This study focuses on an interleukin-12 DNA plasmid vector incorporated into a nanoparticle delivery system, aimed at enhancing anti-cancer immunity. The presentation is scheduled to take place from September 19-21, 2025, in Denver. These recent developments highlight both the financial challenges and ongoing research efforts at Imunon.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.